Aisling Capital — 2025 Investments

2 investments dated 2025 · listed companies and verified rows first · show all

Treeline Biosciencestreeline.bioAug 2025

Treeline develops therapeutics focused on oncology, leveraging insights from clinical practice and laboratory research.

AI & Machine LearningBiotechHealthtechMedical DevicesWatertown, US

Joshua H. Bilenker(Executive Officer, Director, Promoter)Jeffrey Engelman(Executive Officer, Director, Promoter)inJosh Bilenker(Founder)inJosh Bilenker Jeff Engelman(Founder)

BoardKristina Burow(Director)inAli Satvat(Director)

Board seatSteven ElmsAftab Kherani· per SEC Form D

Co-investorsARCH Venture Partners GV (Google Ventures)OrbiMed ARC VENTURES Casdin Capital Exor +3 more

Wugenwugen.comAug 2025 · $115M

Allotera (formerly Wugen) develops allogeneic T-cell therapies.

BiotechHealthtechMedical DevicesSt. Louis, US

Ayman Kabakibi(Executive Officer)inCherry Thomas(Executive Officer)inKumar Srinivasan(Executive Officer, Director)inKeith Vendola(Executive Officer)Daniel M Kemp(Executive Officer, Director)Matthew Cooper(Executive Officer)

Co-investorsAlpha Wave Global BioGenerator Ventures RiverVest Venture Partners Abingworth Fidelity Investments LYZZ Capital

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.